Alvah Wickboldt, MD
Pain Medicine · New Orleans, LANPI 1083971006
Payments from drug & device makers
What this record shows
10 manufacturers reported payments, led by Nevro Corp. at 47.5% of the total. Reporting peaked in 2019 at $3,893 and has fallen 98.0% since, to $80 in 2025.
Across 97 payments — averaging $74.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$3K
- Nalu Medical, Inc.$1K
- Relievant Medsystems, Inc.$931
- Abbott$581
- Boston Scientific$417
- Si-bone, Inc.$340
- plus $265 from 4 others
What the payments were for
- Travel & lodging$2,94341%
- Food & beverage$4,24659%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 43 | $3,413 |
| Nalu Medical, Inc. | 10 | $1,241 |
| Relievant Medsystems, Inc. | 7 | $931 |
| Abbott | 15 | $581 |
| Boston Scientific | 11 | $417 |
| Si-bone, Inc. | 5 | $340 |
| SPR Therapeutics, Inc | 2 | $206 |
| Globus Medical | 1 | $22 |
| Saluda Medical Americas, Inc. | 2 | $21 |
| Avanos Medical | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,189 in reported general payments places this provider in the 70th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $1,737 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $1,163 |
| Celecoxib | 11 | $1,145 |
| Gabapentin | 63 | $677 |
| Tizanidine Hcl | 79 | $523 |
| Diclofenac Sodium | 13 | $143 |
| Pregabalin | 19 | $142 |
| Cyclobenzaprine Hcl | 17 | $116 |
| Naproxen | 14 | $76 |
| Tramadol Hcl | 14 | $40 |
| Meloxicam | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in New Orleans
- Alan KayeNew Orleans$76K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Yashar EshraghiNew Orleans$22K
- Aaron Hanyu-DeutmeyerNew Orleans$17K
- Trevor JohnsonNew Orleans$11K
- Eric RoysterNew Orleans$10K
- Lesley WalshNew Orleans$10K
- Arya BekhradiNew Orleans$6K
- Reda TolbaNew Orleans$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.